Guardant Health, Inc. - GH STOCK NEWS

Guardant Health, Inc. (NASDAQ: GH) announced it will release its financial results for Q4 and the full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET). The event can be streamed live from the company’s website, with an archive available post-event. Guardant Health specializes in precision oncology, offering advanced diagnostic tests like Guardant360 and Guardant Reveal to enhance cancer care.

Guardant Health (Nasdaq: GH) announced positive data from the interim analysis of the COSMOS-CRC-01 study, showcasing the Guardant Reveal™ liquid biopsy test's efficacy in detecting molecular residual disease in early-stage colorectal cancer. The test can identify disease recurrence with a lead time of over six months post-surgery. Additionally, the Guardant360® test demonstrated comparable detection rates for microsatellite instability-high status in advanced gastrointestinal cancers. These findings will be presented at the 2022 ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022.

Guardant Health has initiated the SHIELD LUNG study, enrolling nearly 10,000 patients over 36 months to evaluate its blood test for detecting lung cancer in high-risk individuals aged 50-80. The study will take place across 100 centers in the U.S. and Europe. Lung cancer remains a leading cause of cancer-related deaths, with only 14% of eligible individuals adhering to current screening guidelines. Successful study outcomes could support a PMA submission to the FDA.

Guardant Health (GH) announced a settlement with Foundation Medicine regarding digital sequencing technology patents. Foundation Medicine will pay Guardant Health $25 million and future royalties. This agreement results in the dismissal of all pending patent litigation between the two companies. Guardant Health's Co-CEO, Helmy Eltoukhy, emphasized the significance of this settlement, highlighting the recognition of their scientific discoveries and strong intellectual property rights.

Guardant Health, a leader in precision oncology, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 10 at 12:00 p.m. PT / 3:00 p.m. ET. Investors can access the live and archived webcast through the company’s website. Guardant Health focuses on combating cancer using proprietary tests, including Guardant360® and Guardant Reveal™, aiming to improve outcomes and reduce healthcare costs across the cancer care continuum.

Guardant Health (NASDAQ: GH) announced it has reached a milestone in the ECLIPSE study, enrolling 12,750 patients to evaluate its LUNAR-2 blood test for colorectal cancer (CRC) detection. The study aims to support a PMA submission to the U.S. FDA, contingent on positive results. Colorectal cancer screening rates are currently low, and LUNAR-2 seeks to address this by providing a non-invasive blood test to improve access. This milestone reflects the commitment of researchers and participants during challenging times.

Guardant Health (NASDAQ: GH) has announced new data on its Guardant360 liquid biopsy test, presented at the 2021 San Antonio Breast Cancer Symposium. The studies reveal that patients with BRCA1/2 reversion mutations had worse survival outcomes when treated with PARP inhibitors compared to those without. Another study found no significant difference in treatment outcomes for advanced breast cancer patients with PIK3CA mutations regardless of mutation clonality when treated with alpelisib. These findings underscore the utility of the Guardant360 assay in guiding targeted therapy.

Guardant Health (Nasdaq: GH) announced a study published in Nature Medicine demonstrating the effectiveness of the Guardant360 test for guiding treatment in HER2-driven metastatic colorectal cancer. Conducted by the National Cancer Center Hospital East in Japan, the study shows that the test accurately selects patients for HER2-targeted therapy and identifies genetic alterations predicting treatment resistance. The Guardant360 test has been widely accepted, with over 150,000 tests performed and significant clinical validation through peer-reviewed publications.

Guardant Health (Nasdaq: GH) will participate in the 2021 Stifel Healthcare Conference virtually. The management is set for a fireside chat on November 15 at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties can access the live and archived webcast via the company’s website. Guardant Health, a leader in precision oncology, focuses on innovative tests and analytics for cancer care, including its Guardant360 and Guardant Reveal tests.